journal article Open Access Jan 03, 2024

Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma

European Journal of Haematology Vol. 112 No. 5 pp. 662-677 · Wiley
View at Publisher Save 10.1111/ejh.14166
Abstract
Abstract
Chimeric antigen receptor (CAR) T‐cell therapy has become a commercially available treatment option for relapsed or refractory (r/r) diffuse large B‐cell lymphoma (DLBCL) with two or more lines of prior therapies, and recently for high‐risk r/r DLBCL with one prior line of therapy. The successful development of CAR T‐cell therapy for multiple relapsed DLBCL has led to a boom in subsequent trials that investigated its utility in patients with other r/r B‐cell lymphoma subtypes. However, CAR T‐cell therapy is a multistep process that includes leukapheresis and manipulation which take several weeks. Therefore, patients with rapidly progressing or bulky disease may not be able to complete the therapeutic regimen involving CAR T‐cell products. This raises the question of the generalizability of the results of pivotal studies to the entire population. In this review, we summarize the development of CAR‐T cell therapy for B‐cell lymphoma and discuss strategies to further improve the clinical outcomes of this treatment.
Topics

No keywords indexed for this article. Browse by subject →

References
40
[1]
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al.

New England Journal of Medicine 10.1056/nejmoa1707447
[2]
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael R. Bishop, Constantine S. Tam et al.

New England Journal of Medicine 10.1056/nejmoa1804980
[8]
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al.

Blood 10.1182/blood-2017-03-769620
[9]
Neelapu SS "Five‐year follow‐up of ZUMA‐1 supports the curative potential of axicabtagene ciloleucel in refractory large B‐cell lymphoma" Blood (2023)
[14]
Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Caron A. Jacobson, Frederick L. Locke, Long Ma et al.

Transplantation and Cellular Therapy 10.1016/j.jtct.2022.05.026
[16]
Bethge WA "GLA/DRST real‐world outcome analysis of CAR T‐cell therapies for large B‐cell lymphoma in Germany" Blood (2022)
[21]
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al.

Nature Medicine 10.1038/s41591-022-01969-y
[22]
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al.

New England Journal of Medicine 10.1056/nejmoa2116133
[31]
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Dickinson, Carmelo Carlo-Stella, Franck Morschhauser et al.

New England Journal of Medicine 10.1056/nejmoa2206913
[32]
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres et al.

Journal of Clinical Oncology 10.1200/jco.22.01725
[34]
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Jordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama et al.

Blood 10.1182/blood.2020006770
Metrics
6
Citations
40
References
Details
Published
Jan 03, 2024
Vol/Issue
112(5)
Pages
662-677
License
View
Cite This Article
Nobuhiko Yamauchi, Dai Maruyama (2024). Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma. European Journal of Haematology, 112(5), 662-677. https://doi.org/10.1111/ejh.14166
Related

You May Also Like